AIM ImmunoTech Inc. announces that its core drug Ampligen® has reached a critical value inflection point in the field of pancreatic cancer treatment.

The company has formulated a plan to launch a phase 3 clinical study targeting pancreatic cancer. This major decision is strongly supported by several factors: including previously observed positive clinical signals, the drug’s orphan drug designation, and the company’s global intellectual property protection layout. Together, these elements form a solid foundation for advancing the study and mark a new and important stage in the company’s strategic progress in tumor immunotherapy.